Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1212/NXI.0000000000000225 http://scihub22266oqcxt.onion/10.1212/NXI.0000000000000225 C4841645!4841645!27144216     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Neurol+Neuroimmunol+Neuroinflamm 2016 ; 3 (3): ä Nephropedia Template TP {{tp|p=27144216|t=2016. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus |pdf=|usr=}}{{27144216}} gab.com Text Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus JO: Neurol Neuroimmunol Neuroinflamm http://www.kidney.de/pget.php?&tw=1&pmid=27144216 #FOAvip Objective:: To (1) determine the value of the recently proposed criteria of neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and those with limited forms (NMO/LF) with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; and (2) investigate the clinical significance of the serologic status in patients with NMO. Methods:: This was a retrospective, multicenter study of 181 patients fulfilling the 2006 NMO criteria (n = 127) or NMO/LF criteria with AQP4-IgG (n = 54). AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies were tested using cell-based assays. Results:: Patients were mainly white (86%) and female (ratio 6.5:1) with median age at onset 39 years (range 10?77). Compared to patients with NMO and AQP4-IgG (n = 94), those with NMO/LF presented more often with longitudinally extensive transverse myelitis (LETM) (p < 0.001), and had lower relapse rates (p = 0.015), but similar disability outcomes. Nonwhite ethnicity and optic neuritis presentation doubled the risk for developing NMO compared with white race (p = 0.008) or LETM presentation (p = 0.008). Nonwhite race (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.4?13.6) and older age at onset were associated with worse outcome (for every 10-year increase, HR 1.7, 95% CI 1.3?2.2). Patients with NMO and MOG-IgG (n = 9) had lower female:male ratio (0.8:1) and better disability outcome than AQP4-IgG-seropositive or double-seronegative patients (p < 0.001). Conclusions:: In patients with AQP4-IgG, the similar outcomes regardless of the clinical phenotype support the unified term NMOSD; nonwhite ethnicity and older age at onset are associated with worse outcome. Double-seronegative and AQP4-IgG-seropositive NMO have a similar clinical outcome. The better prognosis of patients with MOG-IgG and NMO suggests that phenotypic and serologic classification is useful. Twit Text FOAVip Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus ????Neurol Neuroimmunol Neuroinflamm http://www.kidney.de/pget.php?&tw=1&pmid=27144216 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27144216 #FOAvip English Wikipedia <ref>{{Cite pmid|27144216}}</ref> Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus #MMPMID27144216 Sepúlveda M; Armangué T; Sola-Valls N; Arrambide G; Meca-Lallana JE; Oreja-Guevara C; Mendibe M; Alvarez de Arcaya A; Aladro Y; Casanova B; Olascoaga J; Jiménez-Huete A; Fernández-Fournier M; Ramió-Torrentà L; Cobo-Calvo A; Viñals M; de Andrés C; Meca-Lallana V; Cervelló A; Calles C; Rubio MB; Ramo-Tello C; Caminero A; Munteis E; Antigüedad AR; Blanco Y; Villoslada P; Montalban X; Graus F; Saiz A; Borrego L; Villaverde FJJ; Sempere ÁP; Brieva L; Bonet M; González-Platas M; Puma DL; Llufriu S; Martínez EH; Boyero S; Benito-León J; López JC; Robles R; Foronda J; Navarró L; Millán T; Hervás M; Tallón A; Puertas I; Huertas N; Redondo L; Santos S; Palmí I; Salgado M; Martínez JE; Rubio MA; Oterino A; Ara R; Villaverde R; Ayuso T; Erro E; Marco M; Villar L; Álvarez-Cermeño JC; Agüera E; Bescansa E; Yugüeros I; Tola MA; Orviz-García A; del Haro T; Bestué M; Gómez M; Querol L; Rodríguez E; Ballabriga J; Tintoré M; Castilló J; Rio J; Muñoz D; Midaglia L; Carreón-Guarnizo E; Casado JL; Uclés A; García-Montero R Neurol Neuroimmunol Neuroinflamm 2016[Jun]; 3 (3): ä PMID27144216show ga Objective:: To (1) determine the value of the recently proposed criteria of neuromyelitis optica (NMO) spectrum disorder (NMOSD) that unify patients with NMO and those with limited forms (NMO/LF) with aquaporin-4 immunoglobulin G (AQP4-IgG) antibodies; and (2) investigate the clinical significance of the serologic status in patients with NMO. Methods:: This was a retrospective, multicenter study of 181 patients fulfilling the 2006 NMO criteria (n = 127) or NMO/LF criteria with AQP4-IgG (n = 54). AQP4-IgG and myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) antibodies were tested using cell-based assays. Results:: Patients were mainly white (86%) and female (ratio 6.5:1) with median age at onset 39 years (range 10?77). Compared to patients with NMO and AQP4-IgG (n = 94), those with NMO/LF presented more often with longitudinally extensive transverse myelitis (LETM) (p < 0.001), and had lower relapse rates (p = 0.015), but similar disability outcomes. Nonwhite ethnicity and optic neuritis presentation doubled the risk for developing NMO compared with white race (p = 0.008) or LETM presentation (p = 0.008). Nonwhite race (hazard ratio [HR] 4.3, 95% confidence interval [CI] 1.4?13.6) and older age at onset were associated with worse outcome (for every 10-year increase, HR 1.7, 95% CI 1.3?2.2). Patients with NMO and MOG-IgG (n = 9) had lower female:male ratio (0.8:1) and better disability outcome than AQP4-IgG-seropositive or double-seronegative patients (p < 0.001). Conclusions:: In patients with AQP4-IgG, the similar outcomes regardless of the clinical phenotype support the unified term NMOSD; nonwhite ethnicity and older age at onset are associated with worse outcome. Double-seronegative and AQP4-IgG-seropositive NMO have a similar clinical outcome. The better prognosis of patients with MOG-IgG and NMO suggests that phenotypic and serologic classification is useful. äNeuromyelitis optica spectrum disorders: Comparison according to the p(epmc).pdf DeepDyve Pubget Overpricing